School of Pharmaceutical Science, Institute of Materia Medica, Xinjiang University, Urumqi 830017, China.
Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China.
Int J Mol Sci. 2024 Oct 27;25(21):11532. doi: 10.3390/ijms252111532.
ZKSCAN3 (also known as ZNF306) plays a pivotal role in the regulation of various cellular processes that are fundamental to the development of cancer. It has been widely acknowledged as a key contributor to cancer progression, with its overexpression consistently reported in a broad spectrum of malignancies. Importantly, clinical studies have demonstrated a significant association between elevated ZKSCAN3 levels and adverse prognosis, as well as resistance to therapeutic drugs. Specifically, ZKSCAN3 promotes tumor progression by enhancing multiple hallmark features of cancer and promoting the acquisition of cancer-specific phenotypes. These effects manifest as increased tumor cell proliferation, invasion, and metastasis, accompanied by inhibiting tumor cell apoptosis and modulating autophagy. Consequently, ZKSCAN3 emerges as a promising prognostic marker, and targeting its inhibition represents a potential strategy for anti-tumor therapy. In this review, we provide an updated perspective on the role of ZKSCAN3 in governing tumor characteristics and the underlying molecular mechanisms. Furthermore, we underscore the clinical relevance of ZKSCAN3 and its potential implications for tumor prognosis and therapeutic strategies.
ZKSCAN3（也称为 ZNF306）在调节各种对癌症发展至关重要的细胞过程中发挥着关键作用。它被广泛认为是癌症进展的关键因素，其在广泛的恶性肿瘤中均存在过表达。重要的是，临床研究表明，ZKSCAN3 水平升高与不良预后以及对治疗药物的耐药性之间存在显著关联。具体而言，ZKSCAN3 通过增强癌症的多种标志性特征并促进获得癌症特异性表型来促进肿瘤进展。这些效应表现为肿瘤细胞增殖、侵袭和转移增加，同时抑制肿瘤细胞凋亡并调节自噬。因此，ZKSCAN3 成为有前途的预后标志物，靶向其抑制可能成为抗肿瘤治疗的一种潜在策略。在这篇综述中，我们提供了 ZKSCAN3 在调控肿瘤特征和潜在分子机制方面的最新观点。此外，我们强调了 ZKSCAN3 的临床相关性及其对肿瘤预后和治疗策略的潜在影响。
